Recent News
Read ArticleThe EULAR 2026 Congress in London showcased growing interest in T-cell engagers as a novel strategy to achieve deep B-cell depletion and drug-free remission in refractory rheumatic and musculoskeletal diseases (RMDs).
Imaging in SpA: are we seeing a clearer picture?
As EULAR2026 comes to a close, practical learnings take precedence as clinicians head back to their clinics. Among them, the 2026 EULAR Update on Imaging Recommendations in SpA stands out.
Read Article
Single center study of 102 pts starting JAK inhibitor (72% >50yrs; 77% RA) shows only 27.5% received at least one RZV vaccination dose (Shingrix) & only 3 recv RZV within 30 daysof a JAK inhibitor. ????? (I vaccinate everyone going on a JAKi w/ Shingrix - don't you?) https://t.co/j2jrBIiuOo
Dr. John Cush @RheumNow ( View Tweet)
Risk of Psoriasis is increased 19% by long-term exposure to Particulate Matter (PM2.5 & PM10; adjHR 1.19), while short-term exposure increases risk of psoriasis exacerbation (adjusted OR 1.03). Stronger in younger, urban, lower SES, ever-smokers, & comorbid allergies https://t.co/pd6S13RG1B
Dr. John Cush @RheumNow ( View Tweet)
True or False: Current guidelines for peripheral SpA recommend initiating treatment with TNF inhibitors before trying NSAIDs or conventional synthetic DMARDs. See if you got it right in this week's RheumIQ quiz at https://t.co/6uiqJjYUVo https://t.co/9hHFjaGUdt
Dr. John Cush @RheumNow ( View Tweet)
“Science is organized knowledge. Wisdom is organized life.” - Immanuel Kant
Dr. John Cush @RheumNow ( View Tweet)
LLMs in SLE: From Patient Education to Clinical Decision Support
The emergence of large language models (LLMs) represents a promising shift in how complex diseases such as systemic lupus erythematosus (SLE) are communicated and interpreted across both patient and clinical https://t.co/0rhada36Ji
Dr. John Cush @RheumNow ( View Tweet)
NK Cells Without a CAR: AB-101 Is Neither CAR-T nor CAR-NK
Much of the meeting came for the next CAR T readout. AB-101 drew attention for a different reason. It depletes B cells by a completely different route.
https://t.co/8eZyDxL7wu https://t.co/Nvbj1NQb5A
Dr. John Cush @RheumNow ( View Tweet)
Obinutuzumab drives histologic remission in lupus nephritis
At #EULAR2026, new data from the phase III REGENCY trial add to the case for obinutuzumab in lupus nephritis. Investigators report deep intrarenal B-cell depletion and significantly higher rates of histological https://t.co/13HY1qIDcj
Dr. John Cush @RheumNow ( View Tweet)
RA-ILD in the Age of Treat-to-Target: Put the Probe on the Chest
RA inflammation may be under control, but RA-associated ILD remains a major challenge. At #EULAR2026, experts highlighted that ILD is one of the few RA outcomes not improving in the biologic era. Three new https://t.co/Qujhl3ktRp
Dr. John Cush @RheumNow ( View Tweet)
What’s New in Psoriatic Arthritis: A Whirlwind Tour
At #EULAR2026, Prof. Dennis McGonagle highlighted three key PsA trends: the rise of single-cell and spatial transcriptomics, progress toward personalized care (though not yet fully realized), and the next frontier of defining https://t.co/zN4K92UnW9
Dr. John Cush @RheumNow ( View Tweet)
RA-ILD: Screening risk and genetic susceptibility
Two abstracts presented at EULAR 2026 add important insights into identifying patients at risk for RA-ILD and understanding the genetic mechanisms that may underpin disease development.
https://t.co/IABp8NhUtS https://t.co/j8UHK2GRd7
Dr. John Cush @RheumNow ( View Tweet)
Vasculitis Updates: Glucocorticoid use in AAV and GCA
Vasculitis Updates: Glucocorticoids are the cornerstone of initial therapy for AAV and GCA—quickly reducing inflammation and preserving organs. EULAR has issued recommendations on glucocorticoid use in ANCA‑associated and https://t.co/hIOKyXDxyb
Dr. John Cush @RheumNow ( View Tweet)
EULAR 2026 Rheumatology RoundUp
It’s time for Rheumatology RoundUp from EULAR 2026 from London, UK. Drs. Artie Kavanaugh and Jack Cush review their choice presentations from the meeting, offering their perspectives on impact and applicability.
Read Article
How many CAR-T’s do we need to test drive?
CAR-T at #EULAR2026 raised as many questions as it answered. Here's what we know, what we're still asking, and why the answers matter.
Read Article
Low dose Blinatumomab: Many Relapse with an Unexpected Surprise
Dr. Alfred Kim discusses abstract OP0203 presented at EULAR 2026 in London.
https://t.co/ir9pdwBnH4 https://t.co/yjjgcA2TRv
Dr. John Cush @RheumNow ( View Tweet)
Renal Biopsies in SLE
Dr. Andrea Fava reporting from EULAR 2026 in London.
https://t.co/naCyEAutbb https://t.co/XgdiXY3hiO
Dr. John Cush @RheumNow ( View Tweet)
When Patients with RA Choose Their Treatment, Outcomes Are Better — Here's the Data
Dr. Aurelie Najm discusses abstract OP0204 presented in London at the EULAR 2026 Congress.
https://t.co/hHQFffTXH0 https://t.co/tXv0SnGBz1
Dr. John Cush @RheumNow ( View Tweet)
PsA Topic Panel: EULAR 2026
Join Drs. Jack Cush, Peter Nash, Antoni Chan, and Nelly Ziade for an expert discussion on the most important psoriatic arthritis developments emerging from EULAR 2026. Abstracts discuss: OP0187, OP069, LB0001, POS0668, OP071
https://t.co/S7Fz5YR3V0 https://t.co/treaJ1OzwB
Dr. John Cush @RheumNow ( View Tweet)
Obinutuzumab drives histologic remission in lupus nephritis
At #EULAR2026, new data from the phase III REGENCY trial add to the case for obinutuzumab in lupus nephritis. Investigators report deep intrarenal B-cell depletion and significantly higher rates of histological https://t.co/AlJ5I8s2JE
Dr. John Cush @RheumNow ( View Tweet)
Video
From the Blog
Podcasts
RheumNow EULAR 2026 Rheumatology Round Up
EULAR 2026 RA Topic Panel
CAR-T Topic Panel EULAR 2026
EULAR 2026 PsA Update What's Changing in P
Therapeutic Updates
Psoriatic arthritis and overweight or obesity
Sponsored by Lilly Medical Affairs
Dr. Merola presenting the results from TOGETHER‑PsA, a phase 3b trial evaluating the concomitant use of an IL‑17A antagonist and an incretin receptor agonist in adults with psoriatic arthritis and overweight or obesity.
Read Post
Poster Hall
Sponsored by AbbVie Medical Affairs + Health Impact
